Shopping Cart 0
Cart Subtotal
AED 0

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Heterozygous familial hypercholesterolemia (heFH)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia-Pipeline Review, H2 2018, provides an overview of the Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 1, 1 and 1 respectively.

Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heterozygous familial hypercholesterolemia (heFH)-Overview

Heterozygous familial hypercholesterolemia (heFH)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Heterozygous familial hypercholesterolemia (heFH)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heterozygous familial hypercholesterolemia (heFH)-Companies Involved in Therapeutics Development

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Heterozygous familial hypercholesterolemia (heFH)-Drug Profiles

(bempedoic acid + ezetimibe)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-306-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3745-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heterozygous familial hypercholesterolemia (heFH)-Dormant Projects

Heterozygous familial hypercholesterolemia (heFH)-Discontinued Products

Heterozygous familial hypercholesterolemia (heFH)-Product Development Milestones

Featured News & Press Releases

Aug 27, 2018: Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study

Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

Feb 08, 2018: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia

Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit

Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196

Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection

Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection

Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia

Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

May 24, 2016: New Cholesterol Treatment Now Available for Canadians

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products by Targets, H2 2018 11

Number of Products by Stage and Targets, H2 2018 11

Number of Products by Mechanism of Actions, H2 2018 13

Number of Products by Stage and Mechanism of Actions, H2 2018 13

Number of Products by Routes of Administration, H2 2018 15

Number of Products by Stage and Routes of Administration, H2 2018 15

Number of Products by Molecule Types, H2 2018 17

Number of Products by Stage and Molecule Types, H2 2018 17


List Of Table

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Daewoong Co Ltd, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Esperion Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Gemphire Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Innovent Biologics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by The Medicines Company, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Dormant Projects, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Heterozygous familial hypercholesterolemia (heFH) Therapeutic Products under Development, Key Players in Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Heterozygous familial hypercholesterolemia (heFH) Pipeline Overview, Heterozygous familial hypercholesterolemia (heFH) Pipeline, Heterozygous familial hypercholesterolemia (heFH) Pipeline Assessment


Companies

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Heterozygous familial hypercholesterolemia (heFH)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia-Pipeline Review, H2 2018, provides an overview of the Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 1, 1 and 1 respectively.

Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heterozygous familial hypercholesterolemia (heFH)-Overview

Heterozygous familial hypercholesterolemia (heFH)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Heterozygous familial hypercholesterolemia (heFH)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heterozygous familial hypercholesterolemia (heFH)-Companies Involved in Therapeutics Development

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Heterozygous familial hypercholesterolemia (heFH)-Drug Profiles

(bempedoic acid + ezetimibe)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-306-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3745-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heterozygous familial hypercholesterolemia (heFH)-Dormant Projects

Heterozygous familial hypercholesterolemia (heFH)-Discontinued Products

Heterozygous familial hypercholesterolemia (heFH)-Product Development Milestones

Featured News & Press Releases

Aug 27, 2018: Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study

Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

Feb 08, 2018: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia

Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit

Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196

Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection

Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection

Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia

Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

May 24, 2016: New Cholesterol Treatment Now Available for Canadians

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products by Targets, H2 2018 11

Number of Products by Stage and Targets, H2 2018 11

Number of Products by Mechanism of Actions, H2 2018 13

Number of Products by Stage and Mechanism of Actions, H2 2018 13

Number of Products by Routes of Administration, H2 2018 15

Number of Products by Stage and Routes of Administration, H2 2018 15

Number of Products by Molecule Types, H2 2018 17

Number of Products by Stage and Molecule Types, H2 2018 17


List Of Table

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Daewoong Co Ltd, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Esperion Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Gemphire Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Innovent Biologics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Pipeline by The Medicines Company, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Dormant Projects, H2 2018

Heterozygous familial hypercholesterolemia (heFH)-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Heterozygous familial hypercholesterolemia (heFH) Therapeutic Products under Development, Key Players in Heterozygous familial hypercholesterolemia (heFH) Therapeutics, Heterozygous familial hypercholesterolemia (heFH) Pipeline Overview, Heterozygous familial hypercholesterolemia (heFH) Pipeline, Heterozygous familial hypercholesterolemia (heFH) Pipeline Assessment


Companies

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company